<abstract xmlns="http://www.w3.org/1999/xhtml">
<p>The body’s defense against environmental factors is realized by physical barriers and cells of both the innate and adaptive immune systems. Patients with end stage kidney disease (ESKD), especially those treated by hemodialysis, have changes in both the function and the number or percent of different leukocyte subsets. Changes were described at the level of monocytes and lymphocyte subsets, which are associated with immunodeficiencies and pro-inflammatory status correlated with degenerative changes and increased cardiovascular risk. These abnormalities have been compared over the past years with alterations appearing as a result ageing. Also, similitudes regarding immunosenescence observed in ESKD patients, in combination with chronic inflammation, are described as the so-called “inflammaging syndrome”.</p>
</abstract>

The body’s defense against environmental factors is realized by physical barriers and cells of both the innate and adaptive immune systems. Patients with end stage kidney disease (ESKD), especially those treated by hemodialysis, have changes in both the function and the number or percent of different leukocyte subsets. Changes were described at the level of monocytes and lymphocyte subsets, which are associated with immunodeficiencies and pro-inflammatory status correlated with degenerative changes and increased cardiovascular risk. These abnormalities have been compared over the past years with alterations appearing as a result ageing. Also, similitudes regarding immunosenescence observed in ESKD patients, in combination with chronic inflammation, are described as the so-called “inflammaging syndrome”.

Immune dysfunction in patients with end stage kidney disease; Immunosenescence – Review

Romanian Journal of Internal Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

The body’s defense against environmental factors is realized by physical barriers and cells of both the innate and adaptive immune systems. Patients with end...

Immune dysfunction in patients with end stage kidney disease; Immunosenescence – Review

Pubblicato online: 23 mar 2024

Pagine: 12 - 19

Ricevuto: 02 set 2023

DOI: https://doi.org/10.2478/rjim-2023-0030

Parole chiave
end stage chronic kidney disease, GFR (glomerular filtration rate), hemodialysis, immunosenescence, immunosuppression, inflammaging syndrome

© 2024 Viorica Ileana Bumbea et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Immune dysfunction in patients with end stage kidney disease; Immunosenescence – Review

Pubblicato online: 23 mar 2024

Pagine: 12 - 19

Ricevuto: 02 set 2023

DOI: https://doi.org/10.2478/rjim-2023-0030

Parole chiaveend stage chronic kidney disease, GFR (glomerular filtration rate), hemodialysis, immunosenescence, immunosuppression, inflammaging syndrome

© 2024 Viorica Ileana Bumbea et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Parole chiave
end stage chronic kidney disease, GFR (glomerular filtration rate), hemodialysis, immunosenescence, immunosuppression, inflammaging syndrome